Fragile X Syndrome

by in

Entry	Author	Date	Location
San Diego Life Sciences Roundup: Topera, Afraxis, Trovagene, & More	Bruce V. Bigelow	05/03/13	San Diego
Sage Therapeutics Shifts Gears, Focuses on Rare Form of Epilepsy	Ben Fidler	04/17/13	Boston
Afraxis Licenses its Drug Compounds to Roche Subsidiary Genentech	Bruce V. Bigelow	01/29/13	San Diego
Roche Deal Gives Seaside a Leg Up in Autism Race	Arlene Weintraub	06/26/12	Boston
San Diego’s Afraxis Gets NIH Support to Develop Compound for Rare Fragile X Syndrome	Bruce V. Bigelow	09/26/11	San Diego
Boston’s Autism Mini-Cluster: New Drugs and Diagnostics Target Mysterious Brain Disorders	Ryan McBride	07/22/10	Boston
Torrey Pines Investment Raises $30 Million Toward $150M Target For Next Fund	Bruce V. Bigelow	03/23/10	San Diego
AFraxis CEO Outlines Biotech’s Success With Ultra-Lean Pre-Clinical R&D in Russia	Bruce V. Bigelow	02/26/10	San Diego
Carl Icahn Nominates Scripps Researcher to Biogen Idec Board, BrainCells Pursues New Drug Combo for Depression, Illumina Adds to Oxford Nanopore Investment, & More San Diego Life Sciences News	Bruce V. Bigelow	02/04/10	San Diego
San Diego’s aFraxis Studies Drug Candidates to Treat Fragile X Syndrome	Denise Gellene	02/03/10	San Diego
Autism Gets a Boost: Seaside Therapeutics Raises $30M To Develop First Drugs That Might Work	Luke Timmerman	09/17/09	Boston
Page 1 of 1

Xconomy National